On March 4, the National Health and Health Commission issued the “New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7)”, which is the same as the sixth version, which retains the two drugs chloroquine phosphate and abidor.
Abidor is a broad-spectrum antiviral drug developed by the former Soviet Union Medicinal Chemistry Research Center. It is mainly used to treat upper respiratory tract infections caused by influenza A and B viruses. SARS-CoV and MERS-CoV coronavirus have certain inhibitory activity.
For people who are concerned about the development of new coronary pneumonia drugs, the name Abidor is no stranger. On February 4, Li Lanjuan, a member of the high-level expert group of the National Health Commission and an academician of the Chinese Academy of Engineering, announced the results of his research team in Wuhan-Abidor can effectively inhibit the new coronavirus. In vitro cell experiments showed that Abidor at a concentration of 10-30 micromolar can reduce the coronavirus load and significantly inhibit the virus’s pathological effect on cells.
These studies show that Abidor is active against SARS and MERS virus pathogens, and they also belong to the β-coronavirus and are structurally similar to 2019-nCoV. It is speculated that Abidor can effectively inhibit the new crown virus.
Abidor is a non-nucleoside broad-spectrum antiviral drug with immune enhancement effect, which is used to treat upper respiratory tract infections caused by influenza A and B viruses. The drug was developed by the former Soviet Union Medicinal Chemistry Research Center and was first marketed in Russia in 1993, and was approved for marketing in China in 2006.
Simply put, Abidor mainly blocks viral replication by inhibiting the fusion of the virus and the host cell membrane. In addition, some data indicate that Abidor can induce the body to produce endogenous interferon, which can also regulate and enhance the body’s immune function while interfering with viral replication.
Abidor has conducted many clinical studies in Europe. For children and adults over 6 years of age, it can significantly reduce the incidence of influenza and acute respiratory infections, shorten the course of disease, reduce complications, and play a dual role in prevention and treatment. The drug has little toxic and side effects and is widely used in Russia and Eastern Europe.
Abidore is absorbed in the gastrointestinal tract with a half-life of 15.7 hours (h). The concentration of the drug in the tissue is higher than that in the plasma, suggesting that it has a strong tissue affinity. The drug is metabolized by the liver, excreted into the intestine via bile, and excreted through feces.
Abidor has inhibitory effects on various viruses, including influenza A, B and C viruses, rhinovirus, adenovirus, respiratory syncytial virus, coxsackie virus and coronavirus.
Known mechanisms of action mainly based on anti-influenza viruses:
Prevent virus from entering the cell: block endocytosis: Abidor inhibits virus entry by interfering with clathrin-dependent endocytosis Anti-fusion: Abidor inhibits the fusion of viral lipid membrane-endocytic vesicle membrane, and exerts membrane fusion inhibition effect. Thanks to this mechanism of action, Abidor has a broader antiviral spectrum than oseltamivir.
Inducing interferon: Abidor activates 2,5-oligoadenylate synthetase (OAS) to induce interferon production, degrade viral mRNA, and prevent viral replication. It has a strong effect of inducing interferon, which can induce a sufficient amount of interferon in the local mucosa of the respiratory tract in a short time (24h), and form a broad-spectrum antiviral state on the respiratory tract on the 4th day. Improving the body’s immune function and the ability to engulf the virus is faster than the time it takes to inject the vaccine (generally 14 days).
Improve body immunity: Abidor can activate phagocytic cells and enhance non-specific immunity. Abidor can significantly improve multiple immunological parameters (CD4 +, CD8 +, B cells and serum immunoglobulin) in immunocompromised patients.
Because Abidor is effective in inhibiting various coronaviruses in vitro, it is recommended for the treatment of new coronary pneumonia.
From the current clinical experience, those suspected and diagnosed with new coronary pneumonia should start the treatment of Abidor as soon as possible, and the early treatment effect is better. The common adverse reactions of the drug are mainly gastrointestinal reactions, which can be tolerated by most patients.
